AR019676A1 - Arilalcanoilpiridazinas, un procedimiento para su preparacion, las composiciones farmaceuticas que las contienen, y un procedimiento para obtener estascomposiciones farmaceuticas - Google Patents
Arilalcanoilpiridazinas, un procedimiento para su preparacion, las composiciones farmaceuticas que las contienen, y un procedimiento para obtener estascomposiciones farmaceuticasInfo
- Publication number
- AR019676A1 AR019676A1 ARP990102875A ARP990102875A AR019676A1 AR 019676 A1 AR019676 A1 AR 019676A1 AR P990102875 A ARP990102875 A AR P990102875A AR P990102875 A ARP990102875 A AR P990102875A AR 019676 A1 AR019676 A1 AR 019676A1
- Authority
- AR
- Argentina
- Prior art keywords
- formula
- compound
- atoms
- hal
- procedure
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Virology (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
Abstract
Derivados de la arilalcanoilpiridazina, de formula (1) sus sales aceptables desde el punto de vista fisiologico y sus solvatos, en los cuales B representafenilo no sustituido o mono o polisustituido con R3, Q está ausente o representa alquileno de 1a 4 átomos de C, R1 y R2 representan independientemente -OR4,-S-R4, -SO-R4, -SO(2)-R4, Hal, R1 y R2 juntos también representan -O-CH(2)-O-, R3 representa R4, Hal, OH, OR4, OPh, NO(2), NHR4, N(R4)(2), NHCOR4, NHSO(2)R4 oNHCOOR(4), R4 representa A, cicloalquilo C3-7, alquilencicloalquilo de 5 a 10 átomos de C o alquenilo de 2 a 8 átomos de C, A representa alquilC1-10 átomos de C que puede estar sustituido con 1 a 5 átomos de F y/o Cl y Hal representa F, Cl, Br o I. Estos compuestos actuan como inhibidores de lafosfodiesterasa IV y se emplean para tratar las alergias, el asma, la bronquitis cronica , la dermatitis atopica, la psoriasis y otras enfermedades de la piel,las enfermedades inflamatorias, las autoinmunodeficiencias, la osteoporosis,las reacciones de rechazo a transplantes, la caquexia, el crecimiento o lametástasis de tumores, la sepsis, los trastornos de la memoria, la aterosclerois y el SIDA. Un procedimiento para preparar los compuesto de formula (1) y sussales en donde se hace reaccionar un compuesto de formula (2) en donde R1 y R2 tienen los significados indicados, con un compuesto de formula (3), en dondeB y Q tienen los significados indicados y L representa Cl, Br, OH o un grupo de OH esterificado y reactivo, o se hace reaccionar un compuesto de formula(4) en donde R1, R2 y Q tienen los significados indicados, con un compuesto de formula (5), en donde B tiene el significado indicado y L representaCl, Br, OH o un grupo de OH esterificado y reactivo, y/o se transforma un compuesto básico de formula (1) en una de sus sales por tratamiento con un ácido.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19826841A DE19826841A1 (de) | 1998-06-16 | 1998-06-16 | Arylalkanoylpyridazine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR019676A1 true AR019676A1 (es) | 2002-03-13 |
Family
ID=7871071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990102875A AR019676A1 (es) | 1998-06-16 | 1999-06-16 | Arilalcanoilpiridazinas, un procedimiento para su preparacion, las composiciones farmaceuticas que las contienen, y un procedimiento para obtener estascomposiciones farmaceuticas |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US6417188B1 (es) |
| EP (1) | EP1087946B1 (es) |
| JP (1) | JP4137378B2 (es) |
| KR (1) | KR100673638B1 (es) |
| CN (1) | CN1168720C (es) |
| AR (1) | AR019676A1 (es) |
| AU (1) | AU750019B2 (es) |
| BR (1) | BR9911177A (es) |
| CA (1) | CA2335104C (es) |
| CZ (1) | CZ298805B6 (es) |
| DE (2) | DE19826841A1 (es) |
| ES (1) | ES2277444T3 (es) |
| HU (1) | HUP0102215A3 (es) |
| ID (1) | ID27735A (es) |
| NO (1) | NO317888B1 (es) |
| PL (1) | PL344796A1 (es) |
| SK (1) | SK287362B6 (es) |
| TW (1) | TW515795B (es) |
| WO (1) | WO1999065880A1 (es) |
| ZA (1) | ZA200100418B (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19915364A1 (de) * | 1999-04-06 | 2000-10-12 | Merck Patent Gmbh | Verwendung von Arylalkanoylpyridazinen |
| DE19932315A1 (de) * | 1999-07-10 | 2001-01-11 | Merck Patent Gmbh | Benzoylpyridazine |
| FR2803593B1 (fr) * | 2000-01-06 | 2002-02-15 | Sanofi Synthelabo | Nouvelles tetrahydropyridines, procede pour leur preparation et compositions pharmaceutiques les contenant |
| DE10064997A1 (de) * | 2000-12-23 | 2002-06-27 | Merck Patent Gmbh | Benzoylpyridazine |
| WO2002072103A1 (en) * | 2001-02-12 | 2002-09-19 | Merck Patent Gmbh | Use of type 4 phosphodiesterase inhibitors in myocardial diseases |
| EP1463509A1 (en) * | 2001-10-31 | 2004-10-06 | MERCK PATENT GmbH | Type 4 phosphodiesterase inhibitors and uses thereof |
| CN1585641A (zh) | 2001-11-05 | 2005-02-23 | 默克专利有限公司 | 亚肼基－丙二腈化合物 |
| DE10224888A1 (de) * | 2002-06-05 | 2003-12-24 | Merck Patent Gmbh | Pyridazinderivate |
| DE10225574A1 (de) * | 2002-06-10 | 2003-12-18 | Merck Patent Gmbh | Aryloxime |
| CN102976984B (zh) | 2003-08-29 | 2015-04-08 | 三井化学株式会社 | 农园艺用杀虫剂的制备中间体 |
| KR100904360B1 (ko) | 2004-01-28 | 2009-06-23 | 미쓰이 가가쿠 가부시키가이샤 | 아미드 유도체 및 그 제조 방법 및 그의 살충제로서의 사용방법 |
| EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
| JP2009506069A (ja) | 2005-08-26 | 2009-02-12 | ブレインセルス，インコーポレイティド | ムスカリン性受容体調節による神経発生 |
| CA2625153A1 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| US20070112017A1 (en) | 2005-10-31 | 2007-05-17 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| EP2377531A2 (en) | 2006-05-09 | 2011-10-19 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| FR2953836B1 (fr) | 2009-12-14 | 2012-03-16 | Sanofi Aventis | Nouveaux derives (heterocycle-tetrahydro-pyridine)-(piperazinyl)-1-alcanone et (heterocycle-dihydro-pyrrolidine)-(piperazinyl)-1-alcanone et leur utilisation comme inhibiteurs de p75 |
| EP2606894A1 (en) | 2011-12-20 | 2013-06-26 | Sanofi | Novel therapeutic use of p75 receptor antagonists |
| WO2013106547A1 (en) | 2012-01-10 | 2013-07-18 | President And Fellows Of Harvard College | Beta-cell replication promoting compounds and methods of their use |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19632549A1 (de) * | 1996-08-13 | 1998-02-19 | Merck Patent Gmbh | Arylalkanoylpyridazine |
-
1998
- 1998-06-16 DE DE19826841A patent/DE19826841A1/de not_active Withdrawn
-
1999
- 1999-05-07 JP JP2000554707A patent/JP4137378B2/ja not_active Expired - Fee Related
- 1999-05-07 PL PL99344796A patent/PL344796A1/xx unknown
- 1999-05-07 DE DE59914151T patent/DE59914151D1/de not_active Expired - Lifetime
- 1999-05-07 SK SK1893-2000A patent/SK287362B6/sk not_active IP Right Cessation
- 1999-05-07 ID IDW20010080A patent/ID27735A/id unknown
- 1999-05-07 US US09/719,467 patent/US6417188B1/en not_active Expired - Fee Related
- 1999-05-07 CA CA002335104A patent/CA2335104C/en not_active Expired - Fee Related
- 1999-05-07 KR KR1020007013328A patent/KR100673638B1/ko not_active IP Right Cessation
- 1999-05-07 WO PCT/EP1999/003151 patent/WO1999065880A1/de active IP Right Grant
- 1999-05-07 AU AU42590/99A patent/AU750019B2/en not_active Ceased
- 1999-05-07 CZ CZ20004632A patent/CZ298805B6/cs not_active IP Right Cessation
- 1999-05-07 BR BR9911177-2A patent/BR9911177A/pt not_active IP Right Cessation
- 1999-05-07 CN CNB998074187A patent/CN1168720C/zh not_active Expired - Fee Related
- 1999-05-07 EP EP99939760A patent/EP1087946B1/de not_active Expired - Lifetime
- 1999-05-07 HU HU0102215A patent/HUP0102215A3/hu unknown
- 1999-05-07 ES ES99939760T patent/ES2277444T3/es not_active Expired - Lifetime
- 1999-06-14 TW TW088109913A patent/TW515795B/zh not_active IP Right Cessation
- 1999-06-16 AR ARP990102875A patent/AR019676A1/es not_active Application Discontinuation
-
2000
- 2000-12-15 NO NO20006412A patent/NO317888B1/no not_active IP Right Cessation
-
2001
- 2001-01-15 ZA ZA200100418A patent/ZA200100418B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999065880A1 (de) | 1999-12-23 |
| SK287362B6 (sk) | 2010-08-09 |
| HUP0102215A3 (en) | 2002-05-28 |
| AU4259099A (en) | 2000-01-05 |
| DE19826841A1 (de) | 1999-12-23 |
| ZA200100418B (en) | 2002-05-07 |
| CA2335104C (en) | 2008-03-11 |
| TW515795B (en) | 2003-01-01 |
| ES2277444T3 (es) | 2007-07-01 |
| CZ20004632A3 (cs) | 2001-04-11 |
| CN1168720C (zh) | 2004-09-29 |
| AU750019B2 (en) | 2002-07-11 |
| NO20006412L (no) | 2000-12-15 |
| EP1087946B1 (de) | 2007-01-10 |
| US6417188B1 (en) | 2002-07-09 |
| ID27735A (id) | 2001-04-26 |
| NO20006412D0 (no) | 2000-12-15 |
| PL344796A1 (en) | 2001-11-19 |
| CA2335104A1 (en) | 1999-12-23 |
| KR20010043858A (ko) | 2001-05-25 |
| SK18932000A3 (sk) | 2001-06-11 |
| JP2002518377A (ja) | 2002-06-25 |
| DE59914151D1 (en) | 2007-02-22 |
| CN1305465A (zh) | 2001-07-25 |
| BR9911177A (pt) | 2001-03-13 |
| NO317888B1 (no) | 2004-12-27 |
| JP4137378B2 (ja) | 2008-08-20 |
| HUP0102215A2 (hu) | 2002-03-28 |
| EP1087946A1 (de) | 2001-04-04 |
| KR100673638B1 (ko) | 2007-01-23 |
| CZ298805B6 (cs) | 2008-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR019676A1 (es) | Arilalcanoilpiridazinas, un procedimiento para su preparacion, las composiciones farmaceuticas que las contienen, y un procedimiento para obtener estascomposiciones farmaceuticas | |
| BR9916282A (pt) | Composto, uso de um um composto e método de tratamento | |
| MX9701893A (es) | Nuevos inhibidores de la prostaglandinsintasa. | |
| UY24409A1 (es) | Inhibidores de la matriz metaloproteasa | |
| AR071548A1 (es) | Amidas de acido 3-substituido-4-oxo-3, 4-dihidro-imidazo[5, 1-d]1, 2, 3, 5-tetracina-8-carboxilico, un metodo para su preparacion e intermediarios de su sintesis, una composicion farmaceutica que las comprende y su uso en la fabricacion de medicamentos para el tratamiento de diversos tipos de cancer | |
| PE20020874A1 (es) | Pirimidinas inhibidoras de metaloproteinasas de matriz | |
| ES2190396T3 (es) | Nuevos compuestos amino-triazoles, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. | |
| RU94019984A (ru) | ПИРИДАЗИНЫ КАК ИНГИБИТОРЫ ИНТЕРЛЕЙКИН-1 β ПРЕОБРАЗУЮЩЕГО ФЕРМЕНТА, ФАРМКОМПОЗИЦИЯ НА ИХ ОСНОВЕ И ИХ ПРИМЕНЕНИЕ | |
| PT88992A (pt) | Processo para a preparacao de compostos contendo fosforo uteis como inibidores de colagenase | |
| ES2743921T3 (es) | Derivados de panteteína estables para el tratamiento de la neurodegeneración asociada a pantotenato quinasa (PKAN) y métodos para la síntesis de tales compuestos | |
| AR004672A1 (es) | Derivados de la banzo(g)quinolina, proceso para prepararlos,su utilizacion como productos farmaceuticos, las composiciones farmaceuticas que los contieneny los metodos de tratamiento de la depresion, ansiedad y desordenes bipolares que utilizan dichos compuestos. | |
| AR009379A1 (es) | Derivados de acido piperidin-cetocarboxilico, su uso y composiciones farmaceuticas que los contienen | |
| BR9807763A (pt) | Composto, uso do mesmo, composição farmacêutica, e, processos para inibir a liberação intracelular do fator alfa da necrose tumoral, para inibir uma metaloprotease matriz, para inibição do escoamento de ectodomìnios de poteina da superfìcie da célula, para inibir o crescimento de metástases tumorais, ou um processo para o tratamento de diabete, ou um processo para o tratamento de artrite, em um sujeito mamìfero. | |
| Mangold | Synthesis and biosynthesis of alkoxylipids | |
| MY105158A (en) | Substituted 4-aminoquinoline derivatives as gastric acid secretion inhibutors. | |
| AR021068A1 (es) | Benzoilpiridazinas y procedimientos para elaborarlas; preparados farmaceuticos que las contienen y procedimiento para elaborarlos, y utilizacion de dichasbenzoilpiridazinas | |
| RU2013151867A (ru) | Ингибиторы гидролазы амидов жирных кислот для лечения боли | |
| DE3474140D1 (en) | Imidazole-ethanol esters | |
| BR0208499A (pt) | ácido 3-heterociclilpropanohidroxâmico como inibidores de procolágeno c-proteinase | |
| ES2777533T3 (es) | Lípidos oxidados y sus métodos de uso | |
| DK149058C (da) | Analogifremgangsmaade til fremstilling af 4-(4,4-(diphenyl)butyl)-1-acylpiperaziner eller syreadditionssalte deraf | |
| MY130320A (en) | 1-bromoethyl ethyl carbonate and its use in the preparation of 1''- ethoxycarbonyloxyethyl esters of penicillins and novel intermediates, methods for its preparation and 1-bromoethylchloroformate and 1-bromoethylbromoformate obtained as intermediates | |
| ES8801278A1 (es) | Procedimiento para la obtencion de azabicicloheptanos sustituidos | |
| EP3412652A1 (en) | Inhibitors of rac1 and uses thereof for treating cancers | |
| DK148058C (da) | Analogifremgangsmaade til fremstilling af thiazolderivater eller syreadditionssalte deraf |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |